CN107820429B - 包含小分子整联蛋白受体-配体激动剂佐剂的用于免疫治疗的新型组合物和方法 - Google Patents

包含小分子整联蛋白受体-配体激动剂佐剂的用于免疫治疗的新型组合物和方法 Download PDF

Info

Publication number
CN107820429B
CN107820429B CN201680036891.3A CN201680036891A CN107820429B CN 107820429 B CN107820429 B CN 107820429B CN 201680036891 A CN201680036891 A CN 201680036891A CN 107820429 B CN107820429 B CN 107820429B
Authority
CN
China
Prior art keywords
amino
thienylmethyl
bis
cells
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680036891.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107820429A8 (zh
CN107820429A (zh
Inventor
达雷恩·G·伍德赛德
彼得·范德斯利切
阿潘德拉·K·马拉地
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qishan Pharmaceutical Co ltd
Texas Medical Center
Original Assignee
Qishan Pharmaceutical Co ltd
Texas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qishan Pharmaceutical Co ltd, Texas Medical Center filed Critical Qishan Pharmaceutical Co ltd
Publication of CN107820429A publication Critical patent/CN107820429A/zh
Publication of CN107820429A8 publication Critical patent/CN107820429A8/zh
Application granted granted Critical
Publication of CN107820429B publication Critical patent/CN107820429B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by a specific adjuvant, e.g. cytokines or CpG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680036891.3A 2015-04-29 2016-04-28 包含小分子整联蛋白受体-配体激动剂佐剂的用于免疫治疗的新型组合物和方法 Active CN107820429B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562154554P 2015-04-29 2015-04-29
US62/154,554 2015-04-29
US15/140,711 US10342866B2 (en) 2015-04-29 2016-04-28 Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants
US15/140,711 2016-04-28
PCT/US2016/029683 WO2016176400A2 (en) 2015-04-29 2016-04-28 Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants

Publications (3)

Publication Number Publication Date
CN107820429A CN107820429A (zh) 2018-03-20
CN107820429A8 CN107820429A8 (zh) 2018-06-01
CN107820429B true CN107820429B (zh) 2022-08-16

Family

ID=57198770

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680036891.3A Active CN107820429B (zh) 2015-04-29 2016-04-28 包含小分子整联蛋白受体-配体激动剂佐剂的用于免疫治疗的新型组合物和方法

Country Status (10)

Country Link
US (5) US10342866B2 (enExample)
JP (2) JP2018514562A (enExample)
KR (3) KR20240052078A (enExample)
CN (1) CN107820429B (enExample)
AU (1) AU2016254034B2 (enExample)
CA (1) CA2984316A1 (enExample)
IL (1) IL255297B (enExample)
MX (2) MX2017013859A (enExample)
SG (2) SG11201708846XA (enExample)
WO (1) WO2016176400A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240052078A (ko) * 2015-04-29 2024-04-22 7 힐즈 인터레스츠 엘엘씨 소분자 인테그린 수용체-리간드 작용제 보강제를 포함하는 면역치료를 위한 새로운 조성물과 방법
US11311619B2 (en) * 2016-04-28 2022-04-26 7 Hills Pharma Inc. and Texas Heart Institute Integrin activator vaccine compositions
JP7069032B2 (ja) * 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
WO2018112364A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating melanoma
WO2018112360A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
WO2021034697A1 (en) * 2019-08-16 2021-02-25 The Regents Of The University Of California Combined cancer therapy involving chemical activation of integrins and targeted cell immunotherapy
US12109263B2 (en) * 2020-09-10 2024-10-08 7 Hills Pharma LLC Integrin agonists or activating compounds and methods for making and using same
KR20240046893A (ko) * 2021-08-10 2024-04-11 텍사스 하트 인스티튜트 아미노아릴-인테그린 작용제 화합물
CA3257474A1 (en) * 2022-05-03 2023-11-09 7 Hills Pharma Inc. NEW LIPID-BASED SMALL MOLECULES INTEGRN LIGAND-RECEPTOR AGONIST SUPPORT COMPOSITIONS, PHARMACEUTICAL INTEGRN AGONIST ADJUVANT COMPOSITIONS PREPARED FROM THESE, AND THEIR PROCESSES FOR MANUFACTURE AND USE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803237A (zh) * 2009-06-12 2012-11-28 埃科特莱茵药品有限公司 作为alx受体激动剂的噁唑和噻唑衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4505227B2 (ja) * 2001-12-20 2010-07-21 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
AU2005249566B2 (en) * 2004-06-04 2010-11-11 Genentech, Inc. Method for treating multiple sclerosis
CN101227885A (zh) * 2005-07-26 2008-07-23 株式会社资生堂 皱纹防止·改善剂
WO2009000406A1 (en) * 2007-06-22 2008-12-31 Bayer Healthcare Ag Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US9023876B2 (en) 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
ES2677668T3 (es) * 2010-11-16 2018-08-06 Texas Heart Institute Agonistas que mejoran la unión de células que expresan integrina a receptores de integrina
AU2015217142B2 (en) 2014-02-12 2020-04-09 7 Hills Pharma LLC Compositions and methods to improve the homing and grafting of hematopoetic stem cells
CA2954175C (en) 2014-07-01 2023-07-25 Upendra K. Marathi Compositions and methods to improve adoptive cell therapies
KR20240052078A (ko) * 2015-04-29 2024-04-22 7 힐즈 인터레스츠 엘엘씨 소분자 인테그린 수용체-리간드 작용제 보강제를 포함하는 면역치료를 위한 새로운 조성물과 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803237A (zh) * 2009-06-12 2012-11-28 埃科特莱茵药品有限公司 作为alx受体激动剂的噁唑和噻唑衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Antibody therapy of cancer;Andrew M. Scott等;《Nature》;20120322;第12卷;摘要部分 *
Integrin Agonists as Adjuvants in Chemotherapy for Melanoma;Martin A. Schwartz等;《Clinical Cancer Research》;20081030;第14卷(第19期);图3、第6196页第2段 *

Also Published As

Publication number Publication date
WO2016176400A2 (en) 2016-11-03
US20220001009A1 (en) 2022-01-06
US12201686B2 (en) 2025-01-21
US10716849B2 (en) 2020-07-21
JP2018514562A (ja) 2018-06-07
WO2016176400A3 (en) 2016-12-08
KR20170136651A (ko) 2017-12-11
JP7244570B2 (ja) 2023-03-22
MX2024002456A (es) 2024-03-08
KR20240052078A (ko) 2024-04-22
KR20240052079A (ko) 2024-04-22
IL255297A0 (en) 2017-12-31
US10709780B2 (en) 2020-07-14
AU2016254034A1 (en) 2017-12-14
US20190343952A1 (en) 2019-11-14
US10709781B2 (en) 2020-07-14
IL255297B (en) 2021-10-31
AU2016254034B2 (en) 2021-11-04
MX2017013859A (es) 2018-07-06
JP2021121602A (ja) 2021-08-26
SG10201911607YA (en) 2020-01-30
CN107820429A8 (zh) 2018-06-01
US20160339098A1 (en) 2016-11-24
US20200054743A1 (en) 2020-02-20
US20190351052A1 (en) 2019-11-21
SG11201708846XA (en) 2017-11-29
CN107820429A (zh) 2018-03-20
CA2984316A1 (en) 2016-11-03
US10342866B2 (en) 2019-07-09

Similar Documents

Publication Publication Date Title
CN107820429B (zh) 包含小分子整联蛋白受体-配体激动剂佐剂的用于免疫治疗的新型组合物和方法
AU2021202260B2 (en) Compositions and methods to improve adoptive cell therapies
US20240189360A1 (en) Compositions and methods to improve the homing and grafting of hematopoetic stem cells
US12109263B2 (en) Integrin agonists or activating compounds and methods for making and using same
US11311619B2 (en) Integrin activator vaccine compositions
AU2019392742A1 (en) Anti-cancer activity of adamantane derivatives
EP3288585A2 (en) Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants
US20200054600A1 (en) Pharmaceutical compositions and methods for systemic treatment of solid tumors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI02 Correction of invention patent application
CI02 Correction of invention patent application

Correction item: Priority

Correct: 62/154,554 2015.04.29 US

False: 62/154,554 2015.04.29 US|15/140,711 2016.04.28 US

Number: 12-01

Page: The title page

Volume: 34

Correction item: Priority

Correct: 62/154,554 2015.04.29 US

False: 62/154,554 2015.04.29 US|15/140,711 2016.04.28 US

Number: 12-01

Volume: 34

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180906

Address after: Texas USA

Applicant after: 7 HILLS INTERESTS LLC

Applicant after: TEXAS HEART INST

Address before: Texas USA

Applicant before: 7 HILLS INTERESTS LLC

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220708

Address after: Texas, USA

Applicant after: Qishan Pharmaceutical Co.,Ltd.

Applicant after: Texas Heart Institute

Address before: Texas,Usa

Applicant before: 7 HILLS INTERESTS LLC

Applicant before: Texas Heart Institute

GR01 Patent grant
GR01 Patent grant